- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03588481
IRIS- DESyne X2 in the IRIS-DES Registry (IRIS DESyne X2)
December 17, 2023 updated by: Seung-Jung Park
Evaluation of Effectiveness and Safety of DESyne X2 in Routine Clinical Practice; A Multicenter, Prospective Observational Study
This study evaluates effectiveness and safety of DESyne X2 in Routine Clinical Practice.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jung-hee Ham, RN
- Phone Number: 82230104728
- Email: cvcrc5@amc.seoul.kr
Study Locations
-
-
-
Incheon, Korea, Republic of
- Recruiting
- Hallym Hospital
-
Contact:
- Soo-han Kim, MD
-
Principal Investigator:
- Soo-han Kim, MD
-
Seoul, Korea, Republic of
- Recruiting
- Korea University Guro Hospital
-
Contact:
- SEUNG-UN NA, MD
-
Principal Investigator:
- SEUNG-UN NA, MD
-
Seoul, Korea, Republic of
- Recruiting
- Asan Medical Hospital
-
Contact:
- Seung-jung Park, MD
-
Principal Investigator:
- Seung-jung Park, MD
-
Seoul, Korea, Republic of
- Withdrawn
- The Catholic University of Korea Seoul St. Mary'S Hospital
-
Seoul, Korea, Republic of
- Terminated
- The Catholic University of Korea, Eunpyeong St. Mary's Hospital
-
Suncheon, Korea, Republic of
- Terminated
- St.Carollo Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
patients with DeSyne X2 stent
Description
Inclusion Criteria:
- Age 19 and more
- Intervention with DeSyne X2 drug-eluting coronary stent
- Agreed with written informed consent form
Exclusion Criteria:
- Intervention with DeSyne X2 drug-eluting coronary stent and other drug eluting stent at the same time
- Life expectancy of 1year and under
- Cardiac shock
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Coronary stenosis
|
Novolimus-eluting stent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite event rate
Time Frame: 1year
|
Death, non-fatal myocardial infarction, Target Vessel Revascularization
|
1year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All death
Time Frame: 5years
|
5years
|
|
Cardiac death
Time Frame: 5years
|
5years
|
|
Myocardial infarction
Time Frame: 5years
|
5years
|
|
Composite event of death or myocardial infarction
Time Frame: 5years
|
5years
|
|
Composite event of cardiac death or myocardial infarction
Time Frame: 5years
|
5years
|
|
Stroke
Time Frame: 5years
|
5years
|
|
Target Vessel revascularization
Time Frame: 5years
|
5years
|
|
Target Lesion revascularization
Time Frame: 5years
|
5years
|
|
Stent thrombosis
Time Frame: 5years
|
stent thrombosis as classified by an Academic Research Consortium
|
5years
|
Procedural success
Time Frame: 3days
|
defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days. |
3days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 28, 2018
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2028
Study Registration Dates
First Submitted
July 5, 2018
First Submitted That Met QC Criteria
July 5, 2018
First Posted (Actual)
July 17, 2018
Study Record Updates
Last Update Posted (Actual)
December 19, 2023
Last Update Submitted That Met QC Criteria
December 17, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMCCV2018-09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Disease
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
National Heart Centre SingaporeUnknownCoronary Heart DiseaseSingapore
Clinical Trials on DESyne X2
-
Seung-Jung ParkCardioVascular Research Foundation, Korea; Amg Korea Co. Ltd.TerminatedCoronary Artery Disease | Angioplasty, Transluminal, Percutaneous CoronaryKorea, Republic of
-
Elixir Medical CorporationCompletedCoronary Artery DiseaseSwitzerland, New Zealand, Belgium, Poland, Australia, Brazil, Germany, Netherlands
-
Elixir Medical CorporationCompleted
-
Yonsei UniversityWithdrawnPatients in the Treatment of Subjects With All-comer Who Are to Undergo PCI
-
Jaeb Center for Health ResearchMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases... and other collaboratorsCompletedType 1 Diabetes MellitusUnited States
-
Unither Pharmaceuticals, FranceAccutest Research Laboratories (I) Pvt. Ltd.Completed
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom... and other collaboratorsCompletedType 1 Diabetes MellitusUnited States
-
Nordic Bioscience A/SCompleted
-
Unither Pharmaceuticals, FranceEXCELYA BordeauxCompletedAcute PainFrance, Russian Federation, Belgium, Hungary, United Kingdom
-
National Taiwan University HospitalNot yet recruitingCoronary Artery Disease